Cargando…

Nilotinib Enhances the Efficacy of Conventional Chemotherapeutic Drugs in CD34(+)CD38(−) Stem Cells and ABC Transporter Overexpressing Leukemia Cells

Incomplete chemotherapeutic eradication of leukemic CD34(+)CD38(−) stem cells is likely to result in disease relapse. The purpose of this study was to evaluate the effect of nilotinib on eradicating leukemia stem cells and enhancing the efficacy of chemotherapeutic agents. Our results showed that AB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Fang, Wang, Xiao-Kun, Shi, Cheng-Jun, Zhang, Hui, Hu, Ya-Peng, Chen, Yi-Fan, Fu, Li-Wu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6270868/ https://www.ncbi.nlm.nih.gov/pubmed/24651611 http://dx.doi.org/10.3390/molecules19033356

Ejemplares similares

Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment
por: Trojani, Alessandra, et al.
Publicado: (2019)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34(−) and immature CD34(+) cells
por: Berger, Marc G., et al.
Publicado: (2021)

CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia
por: Jiang, Zhiwu, et al.
Publicado: (2016)

CD45(dim)CD34(+)CD38(−)CD133(+) cells have the potential as leukemic stem cells in acute myeloid leukemia
por: Heo, Sook-Kyoung, et al.
Publicado: (2020)

Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized
por: Jiang, Zhiwu, et al.
Publicado: (2016)

High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia
por: Plesa, Adriana, et al.
Publicado: (2017)

CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients’ Outcome
por: Fathy El-Metwaly, Noura, et al.
Publicado: (2021)

Similar expression profiles in CD34(+) cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib
por: Patel, Ami B., et al.
Publicado: (2018)

The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2017)

FISH(+)CD34(+)CD38(-) cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome
por: Wang, Libing, et al.
Publicado: (2013)

Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells
por: Kornblau, Steven M., et al.
Publicado: (2013)

Plastic CD34 and CD38 expression in adult B–cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations
por: Lang, F, et al.
Publicado: (2017)

Can CD34(+)CD38(−) lymphoblasts, as likely leukemia stem cells, be a prognostic factor in B-cell precursor acute lymphoblastic leukemia in children?
por: Stolpa, Weronika, et al.
Publicado: (2023)

Nilotinib‐induced bone marrow CD34+/lin‐Ph+ cells early clearance in newly diagnosed CP‐Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study
por: Pungolino, Ester, et al.
Publicado: (2021)

Effect of DLK1 on tumorigenesis in CD34(+)CD38(−) bone marrow cells in myelodysplastic syndromes
por: ZHANG, WEI, et al.
Publicado: (2013)

Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells
Publicado: (1994)

A molecular signature of dormancy in CD34(+)CD38(-) acute myeloid leukaemia cells
por: Al-Asadi, Mazin Gh., et al.
Publicado: (2017)

Direct confirmation of quiescence of CD34+CD38- leukemia stem cell populations using single cell culture, their molecular signature and clinicopathological implications
por: Won, Eun Jeong, et al.
Publicado: (2015)

Interest in Determining the CD34+ CD38− Phenotype in the Diagnosis and Prognosis of Acute Leukemia in Abidjan – Côte d’Ivoire
por: Sawadogo, Duni, et al.
Publicado: (2013)

Imatinib and Nilotinib Inhibit Hematopoietic Progenitor Cell Growth, but Do Not Prevent Adhesion, Migration and Engraftment of Human Cord Blood CD34(+) Cells
por: Belle, Ludovic, et al.
Publicado: (2012)

CD34(+)CD38(−)CD123(+) Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents
por: Vergez, François, et al.
Publicado: (2020)

Targeting CD38 for acute leukemia
por: Zhong, Xushu, et al.
Publicado: (2022)

Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones
por: Al-Mawali, Adhra, et al.
Publicado: (2016)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
por: Zahran, Asmaa M., et al.
Publicado: (2018)

Wnt1 Accelerates an Ex Vivo Expansion of Human Cord Blood CD34(+)CD38(−) Cells
por: Chotinantakul, Kamonnaree, et al.
Publicado: (2013)

A Case of Atypical Hairy Cell Leukemia With CD10+ and CD38+: Diagnosis and Treatment
por: Tuan Nguyen, Tung, et al.
Publicado: (2022)

Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients’ CD34(+)/CD38(−) Leukemia Stem Cells
por: Stukan, Iga, et al.
Publicado: (2022)

KD025, an anti-adipocyte differentiation drug, enhances the efficacy of conventional chemotherapeutic drugs in ABCG2-overexpressing leukemia cells
por: Jing, Wen, et al.
Publicado: (2020)

Targeting of CD34(+)CD38(-) cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia
por: Jawad, Mays, et al.
Publicado: (2012)

Prospective validation of the prognostic relevance of CD34(+)CD38(–) AML stem cell frequency in the HOVON-SAKK132 trial
por: Ngai, Lok Lam, et al.
Publicado: (2023)

Nilotinib hampers the proliferation and function of CD8(+) T lymphocytes through inhibition of T cell receptor signalling
por: Chen, J, et al.
Publicado: (2008)

Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna(®)) with the human ABC drug transporter P-glycoprotein
por: Shukla, Suneet, et al.
Publicado: (2014)

Ginsenoside Rg1 Inhibits Cell Proliferation and Induces Markers of Cell Senescence in CD34+CD38− Leukemia Stem Cells Derived from KG1α Acute Myeloid Leukemia Cells by Activating the Sirtuin 1 (SIRT1)/Tuberous Sclerosis Complex 2 (TSC2) Signaling Pathway
por: Tang, Yan-Long, et al.
Publicado: (2020)

Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin
Publicado: (1996)

HIV-1 infection depletes human CD34(+)CD38(-) hematopoietic progenitor cells via pDC-dependent mechanisms
por: Li, Guangming, et al.
Publicado: (2017)

Further phenotypic characterization of the primitive lineage− CD34+CD38−CD90+CD45RA− hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia
por: Wisniewski, D, et al.
Publicado: (2011)

Clinicopathological significance of CD28 overexpression in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines.
por: Izquierdo, M. A., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_ep8ksjrvoifb89lb1poneuq4eh